Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | THRB | P10828 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MGAM | O43451 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | SI | P14410 | 1/20 | 0.32 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2851364 | 0.86 | ALDH1A1 (0.41) | ALDH1A1THRBLMNASLC15A2MEN1 | |
| SCHEMBL10844850 | 0.85 | MEN1 (0.43) | ALDH1A1THRBLMNASLC15A2MEN1 | |
| SCHEMBL17767286 | 0.82 | ALDH1A1 (0.38) | ALDH1A1THRBLMNASLC15A2MEN1 | |
| SCHEMBL17767284 | 0.82 | ALDH1A1 (0.38) | ALDH1A1THRBLMNASLC15A2MEN1 | |
| SCHEMBL221073 | 0.81 | PTPN1 (0.40) | PTPN1ALDH1A1THRBMEN1CYP1A2 | |
| SCHEMBL27692685 | 0.78 | KMT2A (0.37) | PTPN1LMNAMEN1KMT2A | |
| SCHEMBL2851915 | 0.78 | KMT2A (0.37) | PTPN1LMNAMEN1KMT2A | |
| SCHEMBL28935351 | 0.77 | MEN1 (0.40) | PTPN1ALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL28697226 | 0.76 | MEN1 (0.42) | PTPN1ALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL28871790 | 0.75 | PTPN1 (0.37) | PTPN1ALDH1A1LMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100160670-A1 | NOVEL PROCESS FOR THE PREPARATION OF CHIRAL COMPOUNDS DERIVED FROM HEXANOIC ACID ESTERS AND INTERMEDIATES USED IN THE SYNTHESIS OF CHIRAL-2-(BROMOMETHYL)-2-ETHYLHEXANOIC ACID | AVENTIS PHARMA S.A. (FR) | 2010-06-24 | — | — | US | disclosed |
| US-20090163737-A1 | NOVEL PROCESS FOR THE PREPARATION OF CHIRAL COMPOUNDS DERIVED FROM HEXANOIC ACID ESTERS AND INTERMEDIATES USED IN THE SYNTHESIS OF CHIRAL 2-(BROMOMETHYL)-2-ETHYLHEXANOIC ACID | AVENTIS PHARMA S.A. (FR) | 2009-06-25 | — | — | US | disclosed |
| US-20080108847-A1 | NOVEL PROCESS FOR THE PREPARATION OF CHIRAL COMPOUNDS DERIVED FROM HEXANOIC ACID ESTERS AND INTERMEDIATES USED IN THE SYNTHESIS OF CHIRAL2-(BROMOMETHYL)-2-ETHYLHEXANOIC ACID | AVENTIS PHARMA S.A. (FR) | 2008-05-08 | — | — | US | disclosed |
| US-20040147774-A1 | Novel chiral compounds derived from hexanoic acid esters, preparation process and intermediates, use in the synthesis of chiral 2-(bromomethyl)-2-ethylhexanoic acid | AVENTIS PHARMA S.A. (FR) | 2004-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108847-A1 | NOVEL PROCESS FOR THE PREPARATION OF CHIRAL COMPOUNDS DERIVED FROM HEXANOIC ACID ESTERS AND INTERMEDIATES USED IN THE SYNTHESIS OF CHIRAL2-(BROMOMETHYL)-2-ETHYLHEXANOIC ACID | HCAR2, HCAR3, HCAR1 | PTPN1 4675/4885ALDH1A1 196/4885THRB 445/4885 |
| US-20090163737-A1 | NOVEL PROCESS FOR THE PREPARATION OF CHIRAL COMPOUNDS DERIVED FROM HEXANOIC ACID ESTERS AND INTERMEDIATES USED IN THE SYNTHESIS OF CHIRAL 2-(BROMOMETHYL)-2-ETHYLHEXANOIC ACID | HCAR3, HCAR2, HCAR1 | PTPN1 4638/4885ALDH1A1 163/4885THRB 341/4885 |
| US-20040147774-A1 | Novel chiral compounds derived from hexanoic acid esters, preparation process and intermediates, use in the synthesis of chiral 2-(bromomethyl)-2-ethylhexanoic acid | HCAR2, FFAR2, HCAR3 | PTPN1 4227/4885ALDH1A1 128/4885THRB 507/4885 |
| US-20100160670-A1 | NOVEL PROCESS FOR THE PREPARATION OF CHIRAL COMPOUNDS DERIVED FROM HEXANOIC ACID ESTERS AND INTERMEDIATES USED IN THE SYNTHESIS OF CHIRAL-2-(BROMOMETHYL)-2-ETHYLHEXANOIC ACID | HCAR2, HCAR3, HCAR1 | PTPN1 4580/4885ALDH1A1 160/4885THRB 356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.